CF-301 Activity versus Contemporary Staphylococcus aureus Clinical Isolates from US Hospitals Presented at ASM 2018, June 10, 2018
Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of Staph aureus infective endocarditis Presented at 28th ECCMID, April 24, 2018
Optimal timing of the Co-administration of lysin CF-301 with daptomycin in a rabbit model of infective endocarditis due to MRSA Presented at 28th ECCMID, April 24, 2018
European surveillance study of CF-301 activity against contemporary Staph aureus isolates from Italy, Greece, and Hungary Presented at 28th ECCMID, April 24, 2018
Translational study of the antibiofilm activity of lysin CF-301 in an infected hemodialysis catheter from patient with suspected Staph aureus bacteremia Presented at 28th ECCMID, April 23, 2018
Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA, Europe and South America Presented at ID Week 2017, October 6, 2017
Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus Presented at ID Week 2017, October 6, 2017
Population Phamacokinetic-Pharmacodynamic Assessment of Cardiac Safety Endpoints for CF-301, a First-In-Class Antibacterial Lysin Presented at ASM Microbe 2017, June 3, 2017
Inflammatory Markers in a Phase 1 Placebo Controlled Dose Escalating Study of Intravenous Doses of CF-301 in Human Subjects Presented at ASM Microbe 2017, June 2, 2017
Low Propensity of Resistance Development In Vitro in Staphylococcus aureus with Lysin CF-301 Presented at ASM Microbe 2017, June 2, 2017
